Related Experiment Video
Updated: Jun 3, 2026

Using Reverse Genetics to Manipulate the NSs Gene of the Rift Valley Fever Virus MP-12 Strain to Improve Vaccine Safety and Efficacy
Published on: November 1, 2011
Genome sequence of SG33 strain and recombination between wild-type and vaccine myxoma viruses
Christelle Camus-Bouclainville1, Magalie Gretillat, Robert Py
1French National Institute for Agricultural Research, Toulouse, France. c.camus@envt.fr
Abstract:
Myxomatosis in Europe is the result of the release of a South America strain of myxoma virus in 1952. Several attenuated strains with origins in South America or California have since been used as vaccines in the rabbit industry. We sequenced the genome of the SG33 myxoma virus vaccine strain and compared it with those of other myxoma virus strains. We show that SG33 genome carries a large deletion in its right end. Furthermore, our data strongly suggest that the virus isolate from which SG33 is derived results from an in vivo recombination between a wild-type South America (Lausanne) strain and a California MSD-derived strain. These findings raise questions about the use of insufficiently attenuated virus in vaccination.
Related Concept Videos
Viral Recombination
Viral Mutations
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...

